Soluble CD44 Oral Rinse Biomarker Panel for HNSCC Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for detecting head and neck squamous cell carcinoma (HNSCC) are inadequate, with existing biomarkers showing low sensitivity and specificity, and there is a need for a non-invasive method to identify risk, detect cancer, provide prognosis, and monitor treatment progress.
Innovation Solution
A method using a kit with a saline solution, a cup for oral rinse, antibodies specific to CD44, and reagents for total protein concentration measurement, where soluble CD44 (solCD44) and total protein levels are measured to determine the risk of HNSCC by comparing them to reference levels.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If current biomarker studies use omics approaches to identify candidate markers, then a large pool of potential markers can be screened, but the markers usually fail to perform as well with low sensitivity and specificity
Solution Approach 1:
The patent extracts and focuses on a specific subset of markers (soluble CD44 and total protein) from the large pool of potential omics markers, removing the complexity of analyzing numerous candidates and concentrating on a streamlined panel that achieves superior diagnostic performance
Solution Approach 2:
The patent changes the measurement parameters by quantifying soluble CD44 in ng/mL and total protein in mg/mL, establishing specific reference ranges (soluble CD44: 0-2.2 ng/mL, total protein: 0.6-1.2 mg/mL) that enable reliable differentiation between cancer and non-cancer states
2Reliability
If physical examination followed by biopsy is used as the gold standard for screening, then cancer can be detected, but sensitivity is only 64% and specificity is 74%
Solution Approach 1:
The patent introduces soluble CD44 and total protein as intermediary biomarkers that serve as non-invasive mediators between the cancer state and detection, eliminating the need for direct biopsy while achieving higher sensitivity (85-90%) and specificity (70-80%)
3Reliability
If a panel of methylation markers is used, then cancer detection can be attempted, but sensitivity ranges from 35-85% and specificity from 30-90%, showing poor performance
Solution Approach 1:
The patent changes from detecting methylation status to quantifying protein concentrations (soluble CD44 in ng/mL and total protein in mg/mL), establishing clear reference ranges that enable consistent and reliable cancer detection with reduced variability in performance
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method effectively distinguishes HNSCC from controls with high accuracy, identifies poor prognosis, and monitors treatment effectiveness, demonstrating significant sensitivity and specificity in clinical trials.
Implementation Method 1
at least one antibody that specifically binds CD44
Implementation Method 2
a reagent for determining total protein concentration
Data Source
Figure 1A~1B
Figure 2A~2C
Figure 3
AI summary
Disclosed herein are compositions and methods for determining a risk of cancer, such as head and neck squamous cell carcinoma, in a subject using a bodily fluid sample from the subject and assays for markers such as solCD44 and total protein. Also disclosed are methods of treating a subject based on said risk. Methods of determining the efficacy of a cancer treatment are also disclosed.